MedPath

Effect of Vitamin D Supplementation on the Efficacy of Ustekinumab in the Treatment of Crohn's Disease

Completed
Conditions
Ustekinumab
Vitamin D Supplementation
Crohn's Disease
Clinical Efficacy
Registration Number
NCT05867784
Lead Sponsor
Second Affiliated Hospital of Wenzhou Medical University
Brief Summary

It is uncertain whether vitD3 supplementation is beneficial for the remission of Crohn's disease (CD). The effects of vitD3 supplements on the efficacy of ustekinumab in Chinese CD patients were retrospectively analyzed. Methods: Patients with moderate to severe CD were recorded. These patients were initially treated with UST. VitD3 supplementation was defined as 400IU/d vitD3 supplementation during the first infusion of UST and continued throughout the follow-up period. Disease activity was assessed using Harvey Bradshaw Index.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
80
Inclusion Criteria
  • moderate-to-severe CD
  • Treated with Ustekinumab
Exclusion Criteria
  • had recent supplementation of vitD3
  • pregnant
  • had cognitive/developmental disorders that affected their ability to complete the study procedures
  • had medical illness or therapies potentially affecting bone, nutrition or growth status
  • unknown or untested baseline serum 25(OH)D level

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Serum 25 (OH) D level24 weeks

Vitamin D deficiency is defined as serum 25 (OH) D level\<20 μ g/L

disease activity24weeks

Harvey Bradshaw Index,mild: 0 to 8, moderate: 9 to 16, severe: 17 to 25

Secondary Outcome Measures
NameTimeMethod
Serum 25 (OH) D level8 weeks

Vitamin D deficiency is defined as serum 25 (OH) D level\<20 μ g/L

Trial Locations

Locations (1)

SAHWenzhouMU

🇨🇳

Wenzhou, Zhejiang, China

© Copyright 2025. All Rights Reserved by MedPath